Tags

Type your tag names separated by a space and hit enter

The role of fatty acids in the treatment of ADHD.

Abstract

Several arguments have been proposed to support the hypothesis that supplementation with essential fatty acids (EFAs) could be valuable in the treatment of attention deficit-hyperactivity disorder (ADHD). Indeed, this disorder seems to involve the monoaminergic systems which have been shown to be affected by polyunsaturated fatty acid (PUFA) status, at least in animal models. In addition, several studies have reported abnormal nutritional status with regard to EFAs in ADHD, indicating that lower levels of long-chain PUFAs occur more frequently in the plasma and/or red blood cells of ADHD subjects. Few nutritional EFA supplementation studies have been reported in ADHD to date, but several of them have shown increased blood EFA levels, although their effects on ADHD-related symptoms were not or were only partly successful. The current findings have not yet been clearly proved and require further investigation.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    UMR Inserm U930, CNRS ERL3106, Université François Rabelais, UFR Pharmacie, 31 avenue Monge, 37200 Tours, France. sylvie.chalon@univ-tours.fr

    Source

    Neuropharmacology 57:7-8 2009 Dec pg 636-9

    MeSH

    Animals
    Attention Deficit Disorder with Hyperactivity
    Brain
    Dietary Supplements
    Fatty Acids, Unsaturated
    Humans

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    19715711

    Citation

    Chalon, Sylvie. "The Role of Fatty Acids in the Treatment of ADHD." Neuropharmacology, vol. 57, no. 7-8, 2009, pp. 636-9.
    Chalon S. The role of fatty acids in the treatment of ADHD. Neuropharmacology. 2009;57(7-8):636-9.
    Chalon, S. (2009). The role of fatty acids in the treatment of ADHD. Neuropharmacology, 57(7-8), pp. 636-9. doi:10.1016/j.neuropharm.2009.08.012.
    Chalon S. The Role of Fatty Acids in the Treatment of ADHD. Neuropharmacology. 2009;57(7-8):636-9. PubMed PMID: 19715711.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The role of fatty acids in the treatment of ADHD. A1 - Chalon,Sylvie, Y1 - 2009/08/26/ PY - 2009/06/26/received PY - 2009/08/12/revised PY - 2009/08/18/accepted PY - 2009/9/1/entrez PY - 2009/9/1/pubmed PY - 2010/2/17/medline SP - 636 EP - 9 JF - Neuropharmacology JO - Neuropharmacology VL - 57 IS - 7-8 N2 - Several arguments have been proposed to support the hypothesis that supplementation with essential fatty acids (EFAs) could be valuable in the treatment of attention deficit-hyperactivity disorder (ADHD). Indeed, this disorder seems to involve the monoaminergic systems which have been shown to be affected by polyunsaturated fatty acid (PUFA) status, at least in animal models. In addition, several studies have reported abnormal nutritional status with regard to EFAs in ADHD, indicating that lower levels of long-chain PUFAs occur more frequently in the plasma and/or red blood cells of ADHD subjects. Few nutritional EFA supplementation studies have been reported in ADHD to date, but several of them have shown increased blood EFA levels, although their effects on ADHD-related symptoms were not or were only partly successful. The current findings have not yet been clearly proved and require further investigation. SN - 1873-7064 UR - https://www.unboundmedicine.com/medline/citation/19715711/The_role_of_fatty_acids_in_the_treatment_of_ADHD_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0028-3908(09)00280-9 DB - PRIME DP - Unbound Medicine ER -